JP2016505039A5 - - Google Patents

Download PDF

Info

Publication number
JP2016505039A5
JP2016505039A5 JP2015553775A JP2015553775A JP2016505039A5 JP 2016505039 A5 JP2016505039 A5 JP 2016505039A5 JP 2015553775 A JP2015553775 A JP 2015553775A JP 2015553775 A JP2015553775 A JP 2015553775A JP 2016505039 A5 JP2016505039 A5 JP 2016505039A5
Authority
JP
Japan
Prior art keywords
phenyl
metformin
glp1r agonist
glp1r
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015553775A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016505039A (ja
JP6445459B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/011394 external-priority patent/WO2014113357A1/en
Publication of JP2016505039A publication Critical patent/JP2016505039A/ja
Publication of JP2016505039A5 publication Critical patent/JP2016505039A5/ja
Application granted granted Critical
Publication of JP6445459B2 publication Critical patent/JP6445459B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015553775A 2013-01-17 2014-01-14 Glp1rアゴニストとメトホルミンの組合わせおよび2型糖尿病その他の障害の処置のためのその使用 Active JP6445459B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361753567P 2013-01-17 2013-01-17
US61/753,567 2013-01-17
PCT/US2014/011394 WO2014113357A1 (en) 2013-01-17 2014-01-14 Combinations of a glp1r agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders

Publications (3)

Publication Number Publication Date
JP2016505039A JP2016505039A (ja) 2016-02-18
JP2016505039A5 true JP2016505039A5 (enExample) 2017-02-16
JP6445459B2 JP6445459B2 (ja) 2018-12-26

Family

ID=50030537

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015553775A Active JP6445459B2 (ja) 2013-01-17 2014-01-14 Glp1rアゴニストとメトホルミンの組合わせおよび2型糖尿病その他の障害の処置のためのその使用

Country Status (13)

Country Link
US (1) US20150313908A1 (enExample)
EP (1) EP2945618B1 (enExample)
JP (1) JP6445459B2 (enExample)
KR (1) KR102165434B1 (enExample)
CN (1) CN104968341B (enExample)
AU (1) AU2014207748B2 (enExample)
CA (1) CA2896308C (enExample)
EA (1) EA201591123A1 (enExample)
ES (1) ES2687083T3 (enExample)
IL (1) IL239714A0 (enExample)
MX (1) MX366685B (enExample)
SG (2) SG10201704716XA (enExample)
WO (1) WO2014113357A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019060653A1 (en) 2017-09-22 2019-03-28 Regeneron Pharmaceuticals, Inc. GLP-1 RECEPTOR AGONISTS (GLUCAGON-LIKE PEPTIDE 1) AND USES THEREOF
CA3090823A1 (en) * 2018-05-08 2019-11-14 Vtv Therapeutics Llc Therapeutic uses of glp1r agonists
EP4141008A4 (en) * 2020-04-01 2024-04-17 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. PHARMACEUTICALLY ACCEPTABLE ACID SALT OF GLP-1 RECEPTOR AGONIST FREE BASE, AND PREPARATION METHOD THEREFOR
WO2021196949A1 (zh) * 2020-04-01 2021-10-07 杭州中美华东制药有限公司 一种glp-1受体激动剂的晶型a及其制备方法
CN117042757A (zh) * 2020-12-31 2023-11-10 东国制药株式会社 表现出新溶出速率的包含他达拉非或其药学上可接受的盐和度他雄胺或其药学上可接受的盐的药物组合物
AU2023347206A1 (en) 2022-09-21 2025-04-10 Regeneron Pharmaceuticals, Inc. Methods of treating obesity, diabetes, and liver dysfunction
WO2025158275A1 (en) 2024-01-24 2025-07-31 Pfizer Inc. Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4080472A (en) 1974-03-22 1978-03-21 Societe D'etudes Et D'exploitation De Marques Et Brevets S.E.M.S. Metformin 2-(p-chlorophenoxy)-2-methylpropionate
US20090221652A1 (en) * 2005-11-07 2009-09-03 Geesaman Bard J Combinations of metformin and meglitinide
BRPI0910282A2 (pt) * 2008-03-07 2015-09-01 Transtech Pharma Inc Composto oxadiazo-antraceno para o tratamento de diabetes
MA33219B1 (fr) * 2009-03-30 2012-04-02 Transtech Pharma Inc Derives d'azoanthracene substitues, compositions pharmaceutiques et leurs procedes d'utilisation
US20110064806A1 (en) 2009-09-11 2011-03-17 Transtech Pharma, Inc. Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same
US20110118180A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to metformin
DK2498802T3 (en) * 2009-11-13 2015-04-13 Sanofi Aventis Deutschland Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
US20130040878A1 (en) * 2011-05-13 2013-02-14 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in the treatment of diabetes type 2 patients

Similar Documents

Publication Publication Date Title
JP2016505039A5 (enExample)
TWI329014B (en) Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or h3receptor antagonist/inverse agonist
JP2014528474A5 (enExample)
JP2014532638A (ja) 置換されたキナゾリノンのための経口速放性製剤
JP2015523397A5 (enExample)
JP2009542702A5 (enExample)
JP2009542699A5 (enExample)
JP2017528507A5 (enExample)
WO2009127974A3 (ko) 심혈관계 질환 치료용 약제학적 제제
JP2016510326A5 (enExample)
JP6445459B2 (ja) Glp1rアゴニストとメトホルミンの組合わせおよび2型糖尿病その他の障害の処置のためのその使用
JP2013541583A5 (enExample)
JP2020529440A5 (enExample)
JP2012502103A5 (enExample)
WO2018005801A3 (en) Novel non-systemic tgr5 agonists
WO2018005794A3 (en) Novel non-systemic tgr5 agonists
CN104884051A (zh) 包含吉格列汀和二甲双胍的组合药物及其制备方法
CN104667283B (zh) 一种治疗血脂异常和动脉粥样硬化的复方药物组合
JP2014511365A5 (enExample)
JP2018500297A (ja) 脂肪代謝の調節に供する医薬品の製造のための第一鉄アミノ酸キレートを含む組成物の使用
JP2017509628A5 (enExample)
CN101610760A (zh) 恶病质的治疗
JP2019528290A5 (enExample)
JP2009506043A5 (enExample)
JP2020536068A5 (enExample)